Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture

Shao, Hsiao Yun; Hsu, Huai Sheng; Yu, Shu; Wu, Shang; Hu, Kai; Chang, Ching-Kun; Liu, Chia-Chyi; Chow, Yen‐Hung

doi:10.1016/j.antiviral.2016.03.011

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several pre-clinical studies have shown that mucosal but not systemic immunization with an Ad vaccine induced long-term immunity against pathogens, such as the Ad vector-expressing glycoprotein B of herpes simplex virus type 2 (HSV-2) against HSV-2 [52] . Long-lasting anti-respiratory syncytia virus (RSV) immunity was induced by a nasal Ad vector expressing the fusion protein Ad-RSV-F [53] . Our results also confirmed that the neutralizing antibody against SARS-CoV-2 induced by i.n.…”

Section: Discussionmentioning

confidence: 99%

Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein

Chung

Chen

Yang

et al. 2022

Vaccine

Self Cite

View full text Add to dashboard Cite

A series of recombinant human type 5 adenoviruses that express the full-length or membrane-truncated spike protein (S) of SARS-CoV-2 (AdCoV2-S or AdCoV2-SdTM, respectively) was tested the efficacy against SARS-CoV-2 via intranasal (i.n.) or subcutaneous (s.c.) immunization in a rodent model. Mucosal delivery of adenovirus (Ad) vaccines could induce anti-SARS-CoV-2 IgG and IgA in the serum and in the mucosal, respectively as indicated by vaginal wash (vw) and bronchoalveolar lavage fluid (BALF). Serum anti-SARS-CoV-2 IgG but not IgA in the vw and BALF was induced by AdCoV2-S s.c.. Administration of AdCoV2-S i.n. was able to induce higher anti-SARS-CoV-2 binding and neutralizing antibody levels than s.c. injection. AdCoV2-SdTM i.n. induced a lower antibody responses than AdCoV2-S i.n.. Induced anti-S antibody responses by AdCoV2-S via i.n. or s.c. were not influenced by the pre-existing serum anti-Ad antibody. Novelty, S-specific IgG1 which represented Th2-mediated humoral response was dominantly induced in Ad i.n.-immunized serum in contrast to more IgG2a which represented Th1-mediated cellular response found in Ad s.c.-immunized serum. The activation of S-specific IFN-ɣ and IL-4 in splenic Th1 and Th2 cells, respectively, was observed in the AdCoV2-S i.n. and s.c. groups, indicating the Th1 and Th2 immunity were activated. AdCoV2-S and AdCoV2-SdTM significantly prevented body weight loss and reduced pulmonary viral loads in hamsters. A reduction in inflammation in the lungs was observed in AdCoV-S via i.n. or s.c.-immunized hamsters following a SARS-CoV-2 challenge. It correlated to Th1 cytokine but no inflammatory cytokines secretions found in AdCoV-S i.n. -immunized BALF. These results indicate that intranasal delivery of AdCoV2-S vaccines is safe and potent at preventing SARS-CoV-2 infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein

Chung

Chen

Yang

et al. 2022

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that mucosal but not systemic immunization with an Ad vaccine induced long-term immunity against pathogens, such as the Ad vector-expressing glycoprotein B of herpes simplex virus type 2 (HSV-2) against HSV-2 30 . Long-lasting anti-respiratory syncytia virus (RSV) immunity was induced by a nasal Ad vector expressing the fusion protein Ad-RSV-F 31 . Our results also confirmed that the neutralizing antibody against SARS-CoV-2 induced by i.n.…”

Section: Discussionmentioning

confidence: 99%

Induction of Th1/Th2-Balanced Protection Against SARS-CoV-2 Through Mucosal Delivery of An Adenovirus Vaccine Expressing an Engineered Spike Protein

Chung

Chen

Yang

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

We developed a series of recombinant human type 5 adenoviruses that express the full-length or membrane-truncated spike protein (S) of SARS-CoV-2 (AdCoV2-S or AdCoV2-SdTM, respectively). We tested the immunoprotective efficacy against SARS-CoV-2 via intranasal (i.n.) or subcutaneous (s.c.) immunization in a rodent model following two-dose immunizations. Mucosal delivery of adenovirus (Ad) vaccines could induce anti-SARS-CoV-2 IgG and IgA in the serum and in the mucosal, respectively as indicated by vaginal wash (vw). Serum anti-SARS-CoV-2 IgG but not IgA was induced in the vw by s.c. injection of AdCoV2-S. Intranasal administration of AdCoV2-S was able to induce higher anti-SARS-CoV-2 antibody levels than s.c. injection. Immunization with AdCoV2-SdTM induced a lower antibody response than AdCoV2-S. In addition, the degree of neutralization of clinically isolated SARS-CoV-2 in the serum correlated with the above anti-SARS-CoV-2 responses; the most potent neutralizing activity was observed in the AdCoV2-S i.n. group, and less viral neutralizing activity was observed in response to AdCoV2-S s.c. and AdCoV2dTM i.n. Novelty, S-specific IgG1 which represented Th2-mediated humoral response was dominantly induced in Ad i.n.-immunized serum in contrast to more IgG2a which represented Th1-mediated cellular response found in Ad s.c.-immunized serum. The activation of S-specific IFN-ɣ and IL-4 in Th1 and Th2 cells, respectively, was observed in the AdCoV2s i.n. and s.c. groups, indicating the Th1/Th2-balenced immunity was activated. During the protection study, two doses of i.n. AdCoV2-S or i.n. AdCoV2-SdTM significantly prevented body weight loss and reduced pulmonary viral loads in hamsters. A significant reduction in inflammation in the lungs was observed in AdCoV-S-immunized hamsters following a SARS-CoV-2 challenge. It correlated to Th1 cytokine but no inflammatory cytokines secretions found in i.n. AdCoV-immunized respiratory tract. These results indicate that intranasal delivery of AdCoV2-S vaccines is safe and potent at preventing SARS-CoV-2 infections.

show abstract

“…Up to seven hRSV vaccine candidates have used adenovirus as a vector [103]. Adenovirus vectors expressing the hRSV F protein were immunogenic in mice and in cotton rats [126,127,128]. Further, the vaccine known as PanAd3-RSV showed protection against hRSV in calves [138] and a Phase I clinical trial has been recently completed [131].…”

Section: Prophylaxis Against Hrsv Infectionmentioning

confidence: 99%

Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia—Implications for Vaccine Design

Rey-Jurado

Kalergis

2017

IJMS

View full text Add to dashboard Cite

The human respiratory syncytial virus (hRSV) is the causative agent for high rates of hospitalizations due to viral bronchiolitis and pneumonia worldwide. Such a disease is characterized by an infection of epithelial cells of the distal airways that leads to inflammation and subsequently to respiratory failure. Upon infection, different pattern recognition receptors recognize the virus and trigger the innate immune response against the hRSV. Further, T cell immunity plays an important role for virus clearance. Based on animal studies, it is thought that the host immune response to hRSV is based on a biased T helper (Th)-2 and Th17 T cell responses with the recruitment of T cells, neutrophils and eosinophils to the lung, causing inflammation and tissue damage. In contrast, human immunity against RSV has been shown to be more complex with no definitive T cell polarization profile. Nowadays, only a humanized monoclonal antibody, known as palivizumab, is available to protect against hRSV infection in high-risk infants. However, such treatment involves several injections at a significantly high cost. For these reasons, intense research has been focused on finding novel vaccines or therapies to prevent hRSV infection in the population. Here, we comprehensively review the recent literature relative to the immunological features during hRSV infection, as well as the new insights into preventing the disease caused by this virus.

show abstract

Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture

Cited by 5 publications

References 36 publications

Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein

Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein

Induction of Th1/Th2-Balanced Protection Against SARS-CoV-2 Through Mucosal Delivery of An Adenovirus Vaccine Expressing an Engineered Spike Protein

Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia—Implications for Vaccine Design

Contact Info

Product

Resources

About